New England Journal of Medicine最新文献

筛选
英文 中文
Nivolumab plus Ipilimumab in Advanced Melanoma.
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 DOI: 10.1056/NEJMc2501311
Akhil Santhosh
{"title":"Nivolumab plus Ipilimumab in Advanced Melanoma.","authors":"Akhil Santhosh","doi":"10.1056/NEJMc2501311","DOIUrl":"https://doi.org/10.1056/NEJMc2501311","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1245-1246"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inebilizumab for Treatment of IgG4-Related Disease. 伊奈珠单抗用于治疗 IgG4 相关疾病。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 Epub Date: 2024-11-14 DOI: 10.1056/NEJMoa2409712
John H Stone, Arezou Khosroshahi, Wen Zhang, Emanuel Della Torre, Kazuichi Okazaki, Yoshiya Tanaka, J Matthias Löhr, Nicolas Schleinitz, Lingli Dong, Hisanori Umehara, Marco Lanzillotta, Zachary S Wallace, Mikael Ebbo, George J Webster, Fernando Martinez Valle, Manu K Nayar, Cory A Perugino, Vinciane Rebours, Xinxin Dong, Yanping Wu, Qing Li, Nishi Rampal, Daniel Cimbora, Emma L Culver
{"title":"Inebilizumab for Treatment of IgG4-Related Disease.","authors":"John H Stone, Arezou Khosroshahi, Wen Zhang, Emanuel Della Torre, Kazuichi Okazaki, Yoshiya Tanaka, J Matthias Löhr, Nicolas Schleinitz, Lingli Dong, Hisanori Umehara, Marco Lanzillotta, Zachary S Wallace, Mikael Ebbo, George J Webster, Fernando Martinez Valle, Manu K Nayar, Cory A Perugino, Vinciane Rebours, Xinxin Dong, Yanping Wu, Qing Li, Nishi Rampal, Daniel Cimbora, Emma L Culver","doi":"10.1056/NEJMoa2409712","DOIUrl":"10.1056/NEJMoa2409712","url":null,"abstract":"<p><strong>Background: </strong>IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for treating patients with IgG4-related disease.</p><p><strong>Methods: </strong>In this phase 3, multicenter, double-blind, randomized, placebo-controlled trial, adults with active IgG4-related disease underwent randomization in a 1:1 ratio to receive inebilizumab (300-mg intravenous infusions on days 1 and 15 and week 26) or placebo for a 52-week treatment period. Participants in both groups received identical glucocorticoid tapers. Glucocorticoids were allowed to treat disease flares, but background immunosuppressants were not permitted. The primary end point was the first treated, adjudicated disease flare during the treatment period, assessed in a time-to-event analysis. Key secondary end points were the annualized flare rate and treatment-free and glucocorticoid-free complete remission.</p><p><strong>Results: </strong>A total of 135 participants with IgG4-related disease underwent randomization: 68 participants were assigned to receive inebilizumab and 67 were assigned to receive placebo. Treatment with inebilizumab reduced flare risk; 7 participants (10%) in the inebilizumab group had at least one flare, as compared with 40 participants (60%) in the placebo group (hazard ratio, 0.13; 95% confidence interval [CI], 0.06 to 0.28; P<0.001). The annualized flare rate was lower with inebilizumab than with placebo (rate ratio, 0.14; 95% CI, 0.06 to 0.31; P<0.001). More participants in the inebilizumab group than in the placebo group had flare-free, treatment-free complete remission (odds ratio, 4.68; 95% CI, 2.21 to 9.91; P<0.001) and flare-free, glucocorticoid-free complete remission (odds ratio, 4.96; 95% CI, 2.34 to 10.52; P<0.001). Serious adverse events occurred during the treatment period in 12 of the participants (18%) who received inebilizumab and 6 of the participants (9%) who received placebo.</p><p><strong>Conclusions: </strong>Inebilizumab reduced the risk of flares of IgG4-related disease and increased the likelihood of flare-free complete remission at 1 year, confirming the role of CD19-targeted B-cell depletion as a potential treatment for IgG4-related disease. (Funded by Amgen; MITIGATE ClinicalTrials.gov number, NCT04540497.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1168-1177"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health Care Bridges - Pathways toward Trust in Gaza and Beyond.
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 Epub Date: 2025-03-22 DOI: 10.1056/NEJMp2416553
Yasmeen Abu Fraiha, Abdalrahman Ahmed, Noam Alon, Avner Halperin
{"title":"Health Care Bridges - Pathways toward Trust in Gaza and Beyond.","authors":"Yasmeen Abu Fraiha, Abdalrahman Ahmed, Noam Alon, Avner Halperin","doi":"10.1056/NEJMp2416553","DOIUrl":"10.1056/NEJMp2416553","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1145-1148"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asundexian versus Apixaban in Patients with Atrial Fibrillation.
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 DOI: 10.1056/NEJMc2501201
Marcel Benkhoff, Philipp Mourikis, Amin Polzin
{"title":"Asundexian versus Apixaban in Patients with Atrial Fibrillation.","authors":"Marcel Benkhoff, Philipp Mourikis, Amin Polzin","doi":"10.1056/NEJMc2501201","DOIUrl":"https://doi.org/10.1056/NEJMc2501201","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1247"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NEJM Outbreaks Update - H5N1.
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 Epub Date: 2025-03-05 DOI: 10.1056/NEJMe2502267
Eric J Rubin, Lindsey R Baden, Yoshihiro Kawaoka, Stephen Morrissey
{"title":"NEJM Outbreaks Update - H5N1.","authors":"Eric J Rubin, Lindsey R Baden, Yoshihiro Kawaoka, Stephen Morrissey","doi":"10.1056/NEJMe2502267","DOIUrl":"10.1056/NEJMe2502267","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"e34"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Definition of Failure.
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 Epub Date: 2025-03-22 DOI: 10.1056/NEJMp2414167
Jason Gurney
{"title":"The Definition of Failure.","authors":"Jason Gurney","doi":"10.1056/NEJMp2414167","DOIUrl":"10.1056/NEJMp2414167","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1151-1153"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beta-Blocker Therapy after Acute Myocardial Infarction - To Block or Not to Block?
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 DOI: 10.1056/NEJMclde2410735
Christos P Kotanidis, David J Maron, Tomas Jernberg
{"title":"Beta-Blocker Therapy after Acute Myocardial Infarction - To Block or Not to Block?","authors":"Christos P Kotanidis, David J Maron, Tomas Jernberg","doi":"10.1056/NEJMclde2410735","DOIUrl":"https://doi.org/10.1056/NEJMclde2410735","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1234-1236"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BPROAD - End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes?
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 DOI: 10.1056/NEJMe2501656
Shuchi Anand, Srinivasan Beddhu
{"title":"BPROAD - End of the Road for Debate on Systolic Blood-Pressure Goals in Type 2 Diabetes?","authors":"Shuchi Anand, Srinivasan Beddhu","doi":"10.1056/NEJMe2501656","DOIUrl":"https://doi.org/10.1056/NEJMe2501656","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1230-1232"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asundexian versus Apixaban in Patients with Atrial Fibrillation.
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 DOI: 10.1056/NEJMc2501201
Sam Straw, Klaus K Witte, Helen Philippou
{"title":"Asundexian versus Apixaban in Patients with Atrial Fibrillation.","authors":"Sam Straw, Klaus K Witte, Helen Philippou","doi":"10.1056/NEJMc2501201","DOIUrl":"https://doi.org/10.1056/NEJMc2501201","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1246-1247"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meconium Ileus.
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-03-27 DOI: 10.1056/NEJMicm2409795
Annie Le-Nguyen, Michael-Andrew Assaad
{"title":"Meconium Ileus.","authors":"Annie Le-Nguyen, Michael-Andrew Assaad","doi":"10.1056/NEJMicm2409795","DOIUrl":"https://doi.org/10.1056/NEJMicm2409795","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"392 12","pages":"1215"},"PeriodicalIF":96.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信